

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | PAGE WHERE IT IS REPORTED IN THIS PROTOCOL MANUSCRIPT |
|-----------------------------------|---------|---|---|
| ADMINISTRATIVE INFORMATION | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | PAGE 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | NOT APPLICABLE |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | PAGE 3 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | PAGE 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | PAGE 19 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | PAGE 19 |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | PAGE 19 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | PAGE 19 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | PAGE 19 |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | PAGE 4 TO 8 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | PAGE 8 TO 9 |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, | PAGE 9 TO 10 |

| | | | |
|------------------------------------|-----|--|--------------------------------|
| | | time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | PAGE 11 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | Appendix/Supplemental material |
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | PAGE 12 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | PAGE 12 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | PAGE 13 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | PAGE 13 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | PAGE 13 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | PAGE 13 TO 14 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | PAGE 14 TO 17 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) | PAGE 14 TO 17 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | PAGE 14 TO 17 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | PAGE 14 TO 17 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication | PAGE 17 |

| | | | |
|-----------------------------------|----|--|---------|
| | | bias across studies, selective reporting within studies) | |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | PAGE 18 |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.